UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials

PloS one, 2016-12, Vol.11 (12), p.e0167709-e0167709

2016

Volltextzugriff (PDF)

Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition

The New England journal of medicine, 2004-07, Vol.351 (5), p.427-437

2004

Volltextzugriff (PDF)

Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands

Journal of clinical epidemiology, 2017-08, Vol.88, p.140-147

2017

Volltextzugriff (PDF)

Primary endpoint discrepancies were found in one in ten clinical drug trials. Results of an inception cohort study

Journal of clinical epidemiology, 2017-09, Vol.89, p.199-208

2017

Volltextzugriff (PDF)

Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

Journal of clinical oncology, 2009-08, Vol.27 (23), p.3764-3771

2009

Volltextzugriff (PDF)

Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation

The New England journal of medicine, 2001-07, Vol.345 (3), p.159-164

2001

Volltextzugriff (PDF)

Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic

Annals of surgical oncology, 2007-12, Vol.14 (12), p.3335-3344

2007

Volltextzugriff (PDF)

Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition

Cancer, 2006-06, Vol.106 (11), p.2318-2326

2006

Volltextzugriff (PDF)

Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer

Breast cancer research and treatment, 2006-11, Vol.100 (1), p.109-119

2006

Volltextzugriff (PDF)

Risk factors and risk reduction of breast and ovarian cancer

Current opinion in obstetrics & gynecology, 2003-02, Vol.15 (1), p.63-68

Brekelmans, Cecile T M

2003

Volltextzugriff (PDF)

Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation

Journal of clinical oncology, 2003-05, Vol.21 (9), p.1675-1681

2003

Volltextzugriff (PDF)

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients

Breast cancer research and treatment, 2008-09, Vol.111 (2), p.303-311

2008

Volltextzugriff (PDF)

One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery)

Breast cancer research and treatment, 2002-05, Vol.73 (2), p.97-112

2002

Volltextzugriff (PDF)

Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study

BMJ open, 2015-07, Vol.5 (7), p.e007827-e007827

2015

Volltextzugriff (PDF)

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting

BMC cancer, 2008-07, Vol.8 (1), p.203-203, Article 203

2008

Volltextzugriff (PDF)

Hereditary breast cancer growth rates and its impact on screening policy

European journal of cancer (1990), 2005-07, Vol.41 (11), p.1610-1617

2005

Volltextzugriff (PDF)

Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy

Hereditary cancer in clinical practice, 2009-03, Vol.7 (1), p.6-6, Article 6

2009

Volltextzugriff (PDF)

Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer

Gynecologic oncology, 2005-05, Vol.97 (2), p.476-482

2005

Volltextzugriff (PDF)

Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?

The lancet oncology, 2006-03, Vol.7 (3), p.191-193

2006

Volltextzugriff (PDF)

Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients

Breast cancer research and treatment, 2006, Vol.95 (2), p.117-123

2006

Volltextzugriff (PDF)

Tailoring breast cancer therapy to genetic status

The Lancet (British edition), 2005-05, Vol.365 (9472), p.1672-1673

2005

Volltextzugriff (PDF)

MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling

Breast cancer research and treatment, 2007-08, Vol.104 (2), p.153-157

2007

Volltextzugriff (PDF)

MRI in Breast Cancer

The New England journal of medicine, 2004-11, Vol.351 (21), p.2235-2236

2004

Volltextzugriff (PDF)

Efficacy of Magnetic Resonance Imaging and Mammography for Breast Cancer Screening in Women With a Familial or Genetic Predisposition

Obstetrical & gynecological survey, 2005-02, Vol.60 (2), p.107-109

2005

Volltextzugriff (PDF)

A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false‐negative mammography

International journal of cancer, 2002-11, Vol.102 (1), p.91-95

2002

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(37)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials

Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition

Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands

Primary endpoint discrepancies were found in one in ten clinical drug trials. Results of an inception cohort study

Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation

Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic

Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition

Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer

Risk factors and risk reduction of breast and ovarian cancer

Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation

Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients

One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery)

Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting

Hereditary breast cancer growth rates and its impact on screening policy

Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy

Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer

Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?

Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients

Tailoring breast cancer therapy to genetic status

MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling

MRI in Breast Cancer

Efficacy of Magnetic Resonance Imaging and Mammography for Breast Cancer Screening in Women With a Familial or Genetic Predisposition

A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false‐negative mammography

Suchergebnisse filtern